Published in J Clin Invest on February 16, 2006
Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest (2007) 8.71
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med (2010) 6.45
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (2010) 5.35
Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest (2008) 5.27
Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes (2006) 4.95
Lipid-induced insulin resistance: unravelling the mechanism. Lancet (2010) 4.88
A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects. Nature (2011) 4.44
Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest (2007) 3.88
The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A (2007) 3.76
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature (2014) 3.09
Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A (2006) 2.88
Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci U S A (2007) 2.85
Diacylglycerol-mediated insulin resistance. Nat Med (2010) 2.82
STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol (2009) 2.67
Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med (2012) 2.51
The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol (2010) 2.50
Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity. Cell Metab (2010) 2.44
Fatty acid metabolism: target for metabolic syndrome. J Lipid Res (2008) 2.36
The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab (2009) 2.35
The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature (2014) 2.30
Hepatic triacylglycerol accumulation and insulin resistance. J Lipid Res (2008) 2.14
Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes (2010) 2.10
AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol (2010) 1.93
Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med (2013) 1.91
Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance. J Clin Invest (2007) 1.91
Genetic control of de novo lipogenesis: role in diet-induced obesity. Crit Rev Biochem Mol Biol (2010) 1.89
Energy metabolism in the liver. Compr Physiol (2014) 1.88
Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med (2016) 1.81
Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc Natl Acad Sci U S A (2006) 1.79
Acetyl-coenzyme A carboxylases: versatile targets for drug discovery. J Cell Biochem (2006) 1.77
Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc Natl Acad Sci U S A (2009) 1.77
A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology (2010) 1.71
Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab (2012) 1.64
Inhibition of ADRP prevents diet-induced insulin resistance. Am J Physiol Gastrointest Liver Physiol (2008) 1.64
Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol (2013) 1.56
Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice. J Biol Chem (2011) 1.55
Targeted chemical-genetic regulation of protein stability in vivo. Chem Biol (2012) 1.54
High fat feeding induces hepatic fatty acid elongation in mice. PLoS One (2009) 1.51
A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. Am J Physiol Endocrinol Metab (2010) 1.49
Structure and function of biotin-dependent carboxylases. Cell Mol Life Sci (2012) 1.46
Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice. Mol Cell Biol (2007) 1.44
Resistance to high-fat diet-induced obesity and insulin resistance in mice with very long-chain acyl-CoA dehydrogenase deficiency. Cell Metab (2010) 1.42
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest (2016) 1.37
High sugar-induced insulin resistance in Drosophila relies on the lipocalin Neural Lazarillo. PLoS One (2012) 1.31
Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. Biochim Biophys Acta (2009) 1.28
Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids (2011) 1.23
Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake. Proc Natl Acad Sci U S A (2010) 1.18
Differing endoplasmic reticulum stress response to excess lipogenesis versus lipid oversupply in relation to hepatic steatosis and insulin resistance. PLoS One (2012) 1.15
The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. Annu Rev Nutr (2010) 1.15
Lipoexpediency: de novo lipogenesis as a metabolic signal transmitter. Trends Endocrinol Metab (2011) 1.14
Specific protein kinase C isoforms as transducers and modulators of insulin signaling. Mol Genet Metab (2006) 1.11
Type 2 diabetes: etiology and reversibility. Diabetes Care (2013) 1.06
Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice. Am J Physiol Regul Integr Comp Physiol (2012) 1.05
Probing the role of stearoyl-CoA desaturase-1 in hepatic insulin resistance. J Clin Invest (2006) 1.03
Glycerol-3-phosphate acyltransferase 1 deficiency in ob/ob mice diminishes hepatic steatosis but does not protect against insulin resistance or obesity. Diabetes (2010) 1.03
Tumor progression locus 2 (TPL2) regulates obesity-associated inflammation and insulin resistance. Diabetes (2011) 1.00
Cellular retinol-binding protein type III is a PPARgamma target gene and plays a role in lipid metabolism. Am J Physiol Endocrinol Metab (2008) 0.99
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS One (2016) 0.97
Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides. Diabetes (2012) 0.96
Interaction between mitochondria and the endoplasmic reticulum: implications for the pathogenesis of type 2 diabetes mellitus. Exp Diabetes Res (2011) 0.96
Inhibitory cross-talk between the AMPK and ERK pathways mediates endoplasmic reticulum stress-induced insulin resistance in skeletal muscle. Br J Pharmacol (2013) 0.94
Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation. Mol Metab (2014) 0.94
Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev (2014) 0.92
Hepatic Steatosis as a Marker of Metabolic Dysfunction. Nutrients (2015) 0.92
Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein. J Lipid Res (2012) 0.92
Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc Natl Acad Sci U S A (2016) 0.91
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc (2015) 0.91
Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice. J Lipid Res (2010) 0.91
Impaired PI3K/Akt signal pathway and hepatocellular injury in high-fat fed rats. World J Gastroenterol (2010) 0.89
Role of pyruvate dehydrogenase kinase 4 in regulation of blood glucose levels. Korean Diabetes J (2010) 0.89
Mitochondrial fatty acid oxidation in obesity. Antioxid Redox Signal (2012) 0.88
Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice. Endocrinology (2015) 0.87
The human ACC2 CT-domain C-terminus is required for full functionality and has a novel twist. Acta Crystallogr D Biol Crystallogr (2009) 0.87
Knockdown of the gene encoding Drosophila tribbles homologue 3 (Trib3) improves insulin sensitivity through peroxisome proliferator-activated receptor-γ (PPAR-γ) activation in a rat model of insulin resistance. Diabetologia (2010) 0.84
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease. Dig Dis Sci (2016) 0.83
Loss of regulator of G protein signaling 5 exacerbates obesity, hepatic steatosis, inflammation and insulin resistance. PLoS One (2012) 0.83
PPARδ agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle. Br J Pharmacol (2011) 0.83
Hepatic glucose production pathways after three days of a high-fat diet. Metabolism (2012) 0.82
Focus on therapeutic strategies of nonalcoholic Fatty liver disease. Int J Hepatol (2012) 0.82
De novo lipogenesis in metabolic homeostasis: More friend than foe? Mol Metab (2015) 0.81
ACC2 gene polymorphisms, metabolic syndrome, and gene-nutrient interactions with dietary fat. J Lipid Res (2010) 0.81
The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis. Trends Endocrinol Metab (2016) 0.81
Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice. PLoS One (2013) 0.81
ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content. J Lipid Res (2014) 0.80
Herbal medicines and nonalcoholic fatty liver disease. World J Gastroenterol (2016) 0.79
The effect of ACACB cis-variants on gene expression and metabolic traits. PLoS One (2011) 0.79
Does Diacylglycerol Accumulation in Fatty Liver Disease Cause Hepatic Insulin Resistance? Biomed Res Int (2015) 0.79
IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PLoS One (2014) 0.79
PPARalpha siRNA-treated expression profiles uncover the causal sufficiency network for compound-induced liver hypertrophy. PLoS Comput Biol (2007) 0.78
Susceptibility of podocytes to palmitic acid is regulated by fatty acid oxidation and inversely depends on acetyl-CoA carboxylases 1 and 2. Am J Physiol Renal Physiol (2013) 0.78
Electroacupuncture inhibits weight gain in diet-induced obese rats by activating hypothalamic LKB1-AMPK signaling. BMC Complement Altern Med (2015) 0.78
The increased activity of liver lysosomal lipase in nonalcoholic Fatty liver disease contributes to the development of hepatic insulin resistance. Biochem Res Int (2011) 0.77
Genetic Disruption of Protein Kinase STK25 Ameliorates Metabolic Defects in a Diet-Induced Type 2 Diabetes Model. Diabetes (2015) 0.77
A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease. J Clin Pathol (2007) 0.77
Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. Trends Pharmacol Sci (2017) 0.77
Deregulated coenzyme A, loss of metabolic flexibility and diabetes. Biochem Soc Trans (2014) 0.76
Independent effects of diet and exercise training on fat oxidation in non-alcoholic fatty liver disease. World J Hepatol (2016) 0.75
A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD. PLoS Comput Biol (2016) 0.75
NHE1 deficiency in liver: implications for non-alcoholic fatty liver disease. Biochem Biophys Res Commun (2014) 0.75
A rapid method of total lipid extraction and purification. Can J Biochem Physiol (1959) 173.74
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med (2004) 17.91
Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J (1996) 16.68
Cellular mechanisms of insulin resistance. J Clin Invest (2000) 12.61
Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem (2002) 9.76
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell (2004) 8.06
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem (2004) 7.91
Leptin-replacement therapy for lipodystrophy. N Engl J Med (2002) 7.78
Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab (2002) 6.79
The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem (1997) 6.04
Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science (2001) 5.93
Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature (1999) 5.51
Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A (2001) 5.48
Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes (2005) 5.22
Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med (2004) 5.04
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest (2002) 4.75
Fatty acid synthesis and its regulation. Annu Rev Biochem (1983) 4.74
Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem (2005) 4.13
Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med (2004) 3.88
Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab (2005) 3.87
Transient increase in obese gene expression after food intake or insulin administration. Nature (1995) 2.79
Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes (2001) 2.43
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology (2005) 2.25
The subcellular localization of acetyl-CoA carboxylase 2. Proc Natl Acad Sci U S A (2000) 2.10
Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. Proc Natl Acad Sci U S A (2005) 2.04
Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc Natl Acad Sci U S A (2003) 1.82
Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem (1999) 1.76
Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension (2005) 1.55
Contrasting effects of fish oil and safflower oil on hepatic peroxisomal and tissue lipid content. Am J Physiol Endocrinol Metab (2002) 1.46
Regulation of mammalian acetyl-CoA carboxylase. Biochem Soc Trans (2002) 1.40
Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets (2005) 1.37
Tissue and isoform-selective activation of protein kinase C in insulin-resistant obese Zucker rats - effects of feeding. J Endocrinol (1999) 1.36
Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice. J Clin Invest (2005) 1.35
Protein kinase C is increased in the liver of humans and rats with non-insulin-dependent diabetes mellitus: an alteration not due to hyperglycemia. J Clin Invest (1995) 1.32
Fat in all the wrong places. Nature (2002) 1.30
The regulation of acetyl-CoA carboxylase--a potential target for the action of hypolipidemic agents. Adv Enzyme Regul (1999) 1.07
Diacylglycerol/protein kinase C signalling: a mechanism for insulin resistance? J Intern Med (1993) 1.03
Dissipating excess energy stored in the liver is a potential treatment strategy for diabetes associated with obesity. Diabetes (2005) 0.95
Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med (2004) 18.86
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab (2006) 12.41
Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science (2003) 11.39
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature (2012) 10.74
Mitochondrial dysfunction and type 2 diabetes. Science (2005) 10.25
Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem (2002) 9.76
Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest (2007) 8.71
Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell (2004) 8.58
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem (2004) 7.91
Mechanisms for insulin resistance: common threads and missing links. Cell (2012) 6.85
Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev (2007) 6.53
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med (2010) 6.45
AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A (2002) 5.93
Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes (2005) 5.22
Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med (2004) 5.04
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest (2002) 4.96
Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes (2006) 4.95
Lipid-induced insulin resistance: unravelling the mechanism. Lancet (2010) 4.88
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (2007) 4.83
Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest (2005) 4.81
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest (2002) 4.75
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Etiology of insulin resistance. Am J Med (2006) 4.44
Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases. Cell (2002) 4.38
Effects of fructose vs glucose on regional cerebral blood flow in brain regions involved with appetite and reward pathways. JAMA (2013) 4.30
Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology (2004) 4.25
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature (2011) 4.23
UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature (2008) 3.91
Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest (2007) 3.88
Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab (2005) 3.87
PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest (2004) 3.86
A guide to analysis of mouse energy metabolism. Nat Methods (2011) 3.82
The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A (2007) 3.76
The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes (2002) 3.63
Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet (2003) 3.31
Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech (2010) 3.27
Wireless capsule endoscopy. Gastrointest Endosc (2013) 3.21
FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science (2011) 3.16
Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance. Cell Metab (2010) 3.07
Antisense transcripts are targets for activating small RNAs. Nat Struct Mol Biol (2008) 3.02
Synaptic glutamate release by ventromedial hypothalamic neurons is part of the neurocircuitry that prevents hypoglycemia. Cell Metab (2007) 3.02
Abnormal glucose homeostasis in skeletal muscle-specific PGC-1alpha knockout mice reveals skeletal muscle-pancreatic beta cell crosstalk. J Clin Invest (2007) 3.02
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes (2007) 2.91
Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A (2006) 2.88
Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci U S A (2007) 2.85
Diacylglycerol-mediated insulin resistance. Nat Med (2010) 2.82
Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med (2008) 2.78
Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals. Nat Med (2006) 2.72
Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med (2005) 2.72
Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc Natl Acad Sci U S A (2007) 2.69
STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol (2009) 2.67
Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab (2007) 2.64
Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. Proc Natl Acad Sci U S A (2004) 2.57
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem (2007) 2.55